EUVIMEDEUVIMED entdecken
Open Access

An 18 F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy

Maria Thor, Chen Lee, Lian Sun, Purvi Patel, Aditya Apte, Milan Grkovski, Annemarie F Shepherd, Daphna Y Gelblum, Abraham J Wu, Charles B Simone, Jamie E Chaft, Andreas Rimner und 3 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.266965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Maria Thor und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; thorm@mskcc.org. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation pneumonitis (RP) that develops early (i.e., within 3 mo) (RPEarly) after completion of concurrent chemoradiation (cCRT) leads to treatment discontinuation and poorer survival for patients with stage III non-small cell lung cancer. Since no RPEarly risk model exists, we explored whether published RP models and pretreatment 18F-FDG PET/CT-derived features predict RPEarly Methods: One hundred sixty patients with stage III non-small cell lung cancer treated with cCRT and consolidative immunotherapy were analyzed for RPEarly Three published RP models that included the mean lung dose (MLD) and patient characteristics were examined. Pretreatment 18F-FDG PET/CT normal-lung SUV featured included the following: 10th percentile of SUV (SUVP10), 90th percentile of SUV (SUVP90), SUVmax, SUVmean, minimum SUV, and SD. Associations between models/features and RPEarly were assessed using area under the receiver-operating characteristic curve (AUC), P values, and the Hosmer-Lemeshow test (pHL). The cohort was randomly split, with similar RPEarly rates, into a 70%/30% derivation/internal validation subset.

Results

Twenty (13%) patients developed RPEarly Predictors for RPEarly were MLD alone (AUC, 0.72; P = 0.02; pHL, 0.87), SUVP10, SUVP90, and SUVmean (AUC, 0.70-0.74; P = 0.003-0.006; pHL, 0.67-0.70). The combined MLD and SUVP90 model generalized in the validation subset and was deemed the final RPEarly model (RPEarly risk = 1/[1+e(- x )]; x = -6.08 + [0.17 × MLD] + [1.63 × SUVP90]). The final model refitted in the 160 patients indicated improvement over the published MLD-alone model (AUC, 0.77 vs. 0.72; P = 0.0001 vs. 0.02; pHL, 0.65 vs. 0.87).

Conclusion

Patients at risk for RPEarly can be detected with high certainty by combining the normal lung's MLD and pretreatment 18F-FDG PET/CT SUVP90 This refined model can be used to identify patients at an elevated risk for premature immunotherapy discontinuation due to RPEarly and could allow for interventions to improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRadiation PneumonitisLung NeoplasmsHumansPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18LungImmunotherapyRetrospective Studies

Stichwörter der Autor:innen

PET/CTimmunotherapynon–small cell lung cancerpneumonitisradiation

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; thorm@mskcc.org.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
  • Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Thor, M., Lee, C., Sun, L., Patel, P., Apte, A., Grkovski, M., Shepherd, A. F., Gelblum, D. Y., Wu, A. J., Simone, C. B., Chaft, J. E., Rimner, A., Gomez, D. R., Deasy, J. O., & Shaverdian, N. (2024). An 18 F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266965

Vancouver

Thor M, Lee C, Sun L, Patel P, Apte A, Grkovski M, et al. An 18 F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266965

BibTeX
@article{Thor2024,
  author = {Thor, Maria and Lee, Chen and Sun, Lian and Patel, Purvi and Apte, Aditya and Grkovski, Milan and Shepherd, Annemarie F and Gelblum, Daphna Y and Wu, Abraham J and Simone, Charles B and Chaft, Jamie E and Rimner, Andreas and Gomez, Daniel R and Deasy, Joseph O and Shaverdian, Narek},
  title = {An 18 F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.266965}
}
Kostenlos starten →